Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis.

Ford N, Calmy A, Andrieux-Meyer I, Hargreaves S, Mills EJ, Shubber Z.

AIDS. 2013 Apr 24;27(7):1135-43. doi: 10.1097/QAD.0b013e32835e0752. Review.

PMID:
23299174
2.

Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.

Aaron E, Kempf MC, Criniti S, Tedaldi E, Gracely E, Warriner A, Kumar R, Bachmann LH.

PLoS One. 2010 Sep 7;5(9):e12617. doi: 10.1371/journal.pone.0012617.

3.

Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.

Sturt AS, Dokubo EK, Sint TT.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Review.

PMID:
20238370
4.

Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.

Bera E, Mia R.

S Afr Med J. 2012 Oct 8;102(11 Pt 1):855-9. doi: 10.7196/samj.5700. Review. Erratum in: S Afr Med J. 2012 Dec;102(12):898.

PMID:
23116743
5.

Experience of nevirapine use in a London cohort of HIV-infected pregnant women.

Edwards SG, Larbalestier N, Hay P, de Ruiter A, Welch J, Taylor GP, Easterbrook P.

HIV Med. 2001 Apr;2(2):89-91.

6.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Siegfried N, van der Merwe L, Brocklehurst P, Sint TT.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD003510. doi: 10.1002/14651858.CD003510.pub3. Review.

PMID:
21735394
7.

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.

Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Théry F, Shaffer N, Hargreaves S, Mills EJ, Ford N.

AIDS. 2013 Jun 1;27(9):1403-12. doi: 10.1097/QAD.0b013e32835f1db0. Review.

PMID:
23343913
8.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510. Review. Update in: Cochrane Database Syst Rev. 2011;(7):CD003510.

PMID:
17253490
9.

Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.

Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, Provisor A, Thorpe EM, Paul ME, Foca M, Gandia J, Huang S, Wei LJ, Stevens LM, Watts DH, McNamara J; PACTG 1022 Study Team.

J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):772-6.

PMID:
15213559
10.

[Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital].

Kondo W, Astori Ade A, Gomes Sel-K, Fernandes Rde B, Sasaki Md, Sbalqueiro RL.

Rev Bras Ginecol Obstet. 2008 Jan;30(1):19-24. Portuguese.

11.

Serious toxicity associated with continuous nevirapine-based HAART in pregnancy.

van Schalkwyk JE, Alimenti A, Khoo D, Maan E, Forbes JC, Burdge DR, Gilgoff S, Money DM.

BJOG. 2008 Sep;115(10):1297-302. doi: 10.1111/j.1471-0528.2008.01820.x.

12.

Third-trimester maternal toxicity with nevirapine use in pregnancy.

Joy S, Poi M, Hughes L, Brady MT, Koletar SL, Para MF, Fan-Havard P.

Obstet Gynecol. 2005 Nov;106(5 Pt 1):1032-8.

PMID:
16260522
13.

Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.

Ouyang DW, Brogly SB, Lu M, Shapiro DE, Hershow RC, French AL, Leighty RM, Thompson B, Tuomala RE.

AIDS. 2010 Jan 2;24(1):109-14. doi: 10.1097/QAD.0b013e3283323941.

14.

Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.

Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S, Taweepolcharoen C, Mangclaviraj S, Limpongsanurak S, Jadwattanakul T, Eiamapichart P, Luesomboon W, Apisarnthanarak A, Kamudhamas A, Tangsathapornpong A, Vitavasiri C, Singhakowinta N, Attakornwattana V, Kriengsinyot R, Methajittiphun P, Chunloy K, Preetiyathorn W, Aumchantr T, Toro P, Abrams EJ, El-Sadr W, Phanuphak P.

HIV Med. 2007 Sep;8(6):357-66.

15.

Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.

Peters PJ, Polle N, Zeh C, Masaba R, Borkowf CB, Oyaro B, Omolo P, Ogindo P, Ndivo R, Angira F, Lando R, Fowler MG, Weidle PJ, Thomas TK.

J Int Assoc Physicians AIDS Care (Chic). 2012 Mar-Apr;11(2):142-9. doi: 10.1177/1545109711423445. Epub 2011 Oct 21.

PMID:
22020069
16.

Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.

João EC, Calvet GA, Menezes JA, D'Ippolito MM, Cruz ML, Salgado LA, Matos HJ.

Am J Obstet Gynecol. 2006 Jan;194(1):199-202.

PMID:
16389032
17.

Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital.

Kondo W, Carraro EA, Prandel E, Dias JM, Perini J, Macedo RL, Cornelsen TC, Sbalquiero R, Sasaki Md.

Braz J Infect Dis. 2007 Dec;11(6):544-8.

19.

Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.

Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, Valls Blazquez MC, Narciso P, Perno CF, Mancinelli S, Palombi L.

HIV Med. 2006 Jul;7(5):338-44.

20.

Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.

Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, Rouet F, Becquet R, Leroy V, El-Sadr WM, Abrams EJ, Dabis F.

PLoS Med. 2007 Aug;4(8):e257.

Supplemental Content

Support Center